Medical Economics November 25, 2024
Richard Payerchin

Key Takeaways

  • GLP-1 receptor agonists are proving effective in reducing body mass index and enhancing patient health outcomes.
  • Patients are increasingly interested in understanding the benefits and mechanisms of these antiobesity medications.
  • Dr. Robert Kushner has significantly contributed to obesity research and treatment, focusing on nutrition and lifestyle medicine.
  • Northwestern University’s Feinberg School of Medicine and the Center for Lifestyle Medicine are key institutions in advancing obesity treatment.

A physician researcher and author discusses...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Physician, Provider, Trends
Related Articles:
Gene Therapy for Cardiomyopathies Presents Promising Alternative to Current Treatment
STAT+: 3 trends to watch in biotech in 2025
The GLP-1 dilemma persists into 2025
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions

Share This Article